{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T15:01:35Z","timestamp":1730300495410,"version":"3.28.0"},"reference-count":38,"publisher":"IEEE","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/ieeexplore.ieee.org\/Xplorehelp\/downloads\/license-information\/IEEE.html"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,16]]},"DOI":"10.1109\/tencon50793.2020.9293795","type":"proceedings-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T21:10:24Z","timestamp":1608671424000},"page":"672-677","source":"Crossref","is-referenced-by-count":1,"title":["An Analysis of Patent Application in Pharmaceutical Industry in India"],"prefix":"10.1109","author":[{"given":"Yaeko","family":"Mitsumori","sequence":"first","affiliation":[]}],"member":"263","reference":[{"journal-title":"Hutchinson K paper-based communications","year":"2019","key":"ref38"},{"key":"ref33","article-title":"India Orders Bayer to License a Patented Drug","author":"bajaj","year":"2012","journal-title":"New York Times"},{"journal-title":"Civil Appeal Nos 2706-2716 of 2013 (decision of the Supreme Court of India Civil Appellate Jurisdiction arising out of SLP(C) Nos 20539-20549 of 2009)","year":"0","key":"ref32"},{"journal-title":"Misc Petition Nos 1-5 of\/2007 in TA\/1-5\/2007\/PT\/CH & Misc Petition No 33 of 2008","year":"2009","key":"ref31"},{"journal-title":"W P Nos 24759 and 24760 of 2006 (decisions in the High Court of Judicature at Madras Coram the Hon’ble Mr Justice R Balasubramanian and the Hon’ble Mrs Justice Prabha Sridevan","year":"2007","key":"ref30"},{"journal-title":"Yanagisawa M a hearing at BI Japan Head Office","year":"2019","key":"ref37"},{"journal-title":"Hearing at JPMA head office","year":"2018","author":"fujii","key":"ref36"},{"key":"ref35","article-title":"Consideration of Compulsory License issued on a pharmaceutical patent in India","author":"kubo","year":"2012","journal-title":"IDE-JETRO report IDE-JETRO"},{"journal-title":"Order Granting Compulsory License in the Matter of Natco vs Bayer","year":"2012","key":"ref34"},{"key":"ref10","first-page":"71","article-title":"TRIPS, Pharmaceutical Patents and Health Care for the Poor in India","author":"khanna","year":"2016","journal-title":"ILI Law Review Summer Issue"},{"journal-title":"IBEF Pharmaceuticals IBEF","first-page":"10","year":"2017","key":"ref11"},{"journal-title":"IBEF report","year":"2019","key":"ref12"},{"journal-title":"IBEF Pharmaceuticals IBEF","first-page":"13","year":"2017","key":"ref13"},{"key":"ref14","article-title":"India is the diabetes capital of the World!","author":"malik","year":"2016","journal-title":"ETIMES Life & Style"},{"journal-title":"IBEF Pharmaceuticals IBEF","first-page":"14","year":"2017","key":"ref15"},{"journal-title":"IBEF Pharmaceuticals IBEF","first-page":"15","year":"2017","key":"ref16"},{"journal-title":"History of Indian Patent System Office of the Controller General of Patents Designs Trademarks (CGPDTM)","year":"0","key":"ref17"},{"journal-title":"THE INDIAN PATENTS AND DESIGNS ACT 1911","year":"1911","key":"ref18"},{"key":"ref19","first-page":"31","article-title":"Indian Pharmaceutical Industry: Background of Rapid Growth and Changes after TRIPS” Ch. 2 of \"Japanese Generic Market and Indian\/Chinese Pharmaceutical Industry","author":"minato","year":"2007","journal-title":"IDE-JETRO"},{"journal-title":"IPO annual reports (2002\/03-2016\/17)","year":"0","key":"ref28"},{"key":"ref4","first-page":"50","article-title":"Study of the roles of Section 3d of the Indian Patent Act for lightening negative impact of product patent introduction in 2005 on the Indian Pharmaceutical Industry","author":"mitsumori","year":"2010","journal-title":"Japan MOT Society"},{"journal-title":"Novartis Press Release FAQ on the India Gleevec Patent Case","year":"0","key":"ref27"},{"journal-title":"TRIPS FAQs WTO","article-title":"Which countries are using the general transition periods?","year":"0","key":"ref3"},{"year":"2018","key":"ref6","article-title":"India’s Strong Economy Continues to Lead Global Growth"},{"journal-title":"IQVIA Indian patent application and patent granted data","year":"2017","key":"ref29"},{"key":"ref5","first-page":"213","article-title":"Impact of the introduction of product patent on Indian Pharmaceutical Industry","volume":"25","author":"mitsumori","year":"2012","journal-title":"The Journal of Science Policy and Research Management The Japan Society for Research Policy and Innovation Management"},{"journal-title":"An Overview","year":"0","key":"ref8"},{"journal-title":"ADB","article-title":"Growth Holding Up in Asia and the Pacific, Trade Tensions Pose Risks","year":"2018","key":"ref7"},{"journal-title":"Intellectual property protection and enforcement Understanding the WTO Agreements WTO website","year":"0","key":"ref2"},{"key":"ref9","first-page":"7","article-title":"Developing Innovative Capacity in India to Meet the Health Needs","author":"bhojwani","year":"2005","journal-title":"submitted to The Centre for the Management of Intellectual Property in Health Research and Development (MIHR)"},{"key":"ref1","article-title":"Unique IPR Status of India, A Big Generic Pharmaceutical Country","author":"miyagi","year":"2014","journal-title":"Mitsui & Co Global Strategic Studies Institute (MGSSI) Report"},{"key":"ref20","first-page":"32","article-title":"Indian Pharmaceutical Industry: Background of Rapid Growth and Changes after TRIPS” Ch. 2 of \"Japanese Generic Market and Indian\/Chinese Pharmaceutical Industry","author":"minato","year":"2007","journal-title":"IDE-JETRO"},{"key":"ref22","first-page":"1437","article-title":"India’s First Compulsory License: Its Impact on the Indian Pharmaceutical Mart as well as the World Market","author":"mitsumori","year":"2014","journal-title":"2014 Proceedings of PICMET '14 Infrastructure and Service Integration"},{"journal-title":"Intellectual Property of India","year":"1970","key":"ref21"},{"journal-title":"Indian Patent Office Journal","year":"2005","key":"ref24"},{"journal-title":"Indian Patent Office Journal","year":"2005","key":"ref23"},{"journal-title":"Médecins Sans Frontières Doctors without Borders","article-title":"Q&A Patents in India and Novartis case","year":"0","key":"ref26"},{"key":"ref25","first-page":"41","article-title":"Indian Pharmaceutical Industry: Background of Rapid Growth and Changes after TRIPS” Ch. 2 of \"Japanese Generic Market and Indian\/Chinese Pharmaceutical Industry","author":"minato","year":"2007","journal-title":"IDE-JETRO"}],"event":{"name":"TENCON 2020 - 2020 IEEE REGION 10 CONFERENCE (TENCON)","start":{"date-parts":[[2020,11,16]]},"location":"Osaka, Japan","end":{"date-parts":[[2020,11,19]]}},"container-title":["2020 IEEE REGION 10 CONFERENCE (TENCON)"],"original-title":[],"link":[{"URL":"http:\/\/xplorestaging.ieee.org\/ielx7\/9293567\/9293692\/09293795.pdf?arnumber=9293795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T15:18:21Z","timestamp":1656602301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ieeexplore.ieee.org\/document\/9293795\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1109\/tencon50793.2020.9293795","relation":{},"subject":[],"published":{"date-parts":[[2020,11,16]]}}}